dr. verstovsek on accelerated phase myelofibrosis
Published 5 years ago • 368 plays • Length 2:10Download video MP4
Download video MP3
Similar videos
-
1:45
dr. verstovsek on the manifest trial with cpi-0610 in myelofibrosis
-
2:16
dr. verstovsek on limitations of the current treatment landscape of myelofibrosis
-
1:48
dr. verstovsek on examining cpi-0610 in myelofibrosis
-
1:21
dr. verstovsek discusses immunotherapy in myelofibrosis
-
24:31
managing myelofibrosis in 2021 - dr. srdan verstovsek
-
1:33
outcomes of reduced intensity allosct in patients with accelerated-phase myelofibrosis
-
39:34
dr. verstovsek, md, phd-new approaches for mf
-
9:56
myelofibrosis: diagnosis and risk stratification
-
1:19
dr. srdan verstovsek on jak2 inhibitors as a treatment for myelofibrosis
-
9:29
ruxolitinib’s role in treating myelofibrosis
-
1:49
dr. verstovsek on benefit of ruxolitinib in polycythemia vera
-
1:30
the importance of intervention in chronic phase myelofibrosis
-
1:10
dr. bradley on the utility of ruxolitinib in myelofibrosis and polycythemia vera
-
2:19
dr. verstovsek on toxicity profile of ruxolitinib in mpns
-
23:08
clonal evolution of mpn to accelerated or blastic phase: therapeutic insights
-
1:45
evaluating cpi-0610 as treatment of patients with myelofibrosis
-
4:20
primary myelofibrosis: risk stratification
-
1:02
dr. kremyanskaya on unmet needs in myelofibrosis
-
3:20
promising et, pv & myelofibrosis therapies in development